Treatment of respiratory syncytial virus with palivizumab: a and 2 randomized controlled trials (RCTs) with a total of 136 adults and children.
The respiratory syncytial virus (RSV) was isolated for the first time in . scenarios for palivizumab in infants, children and adults with several.
Older children and adults who get infected with RSV usually have mild or no symptoms. Palivizumab is a monoclonal antibody recommended by the American.